Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Significantly Reduces PSA Levels in Human Prostate Cancer Cells

PSA is a validated FDA-recognized clinical endpoint in assessing prostate cancer treatment response; Telomir-1 lowered PSA levels in a dose-related manner. MIAMI, FLORIDA / ACCESS Newswire / November ...
Science Daily

New study finds cancer-linked compounds in common foods

Scientists have found that common foods can contain hidden contaminants formed during cooking or through environmental ...
TMCnet

ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference

The fireside chat will be held at 3:25pm Eastern Time and a live webcast of the presentation may be accessed by visiting the Events page of the Company’s website at www.promisneurosciences.com. The ...

Enzyme discovered in cyanobacteria can add phosphate groups to therapeutic peptides

Researchers from CIIMAR and the University of Helsinki have discovered a new biochemical modification in natural ...

Germany stagnates in innovation ranking as rivals surge ahead

The ranking, which has analysed the innovation capacity of major economies since 2005, is again led by smaller, highly ...

COVID vaccine tech could limit snakebite venom damage

The same technology used in COVID-19 vaccines could help prevent muscle damage from snakebites, according to a study ...
AccessWDUN

Blue Lake Biotechnology to Resume Enrollment of RSV-negative Toddlers in Phase 1/2a Clinical Trial of BLB201

Blue Lake Biotechnology to Resume Enrollment of RSV-negative Toddlers in Phase 1/2a Clinical Trial of BLB201The Associated PressATHENS, Ga. & SAN JOSE, Calif. ATHENS, Ga. & SAN JOSE, Calif.–(BUSINESS ...
The Globe and Mail

MAIA Biotechnology’s Phase III Study: A New Hope for Advanced NSCLC Treatment

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. MAIA Biotechnology, Inc. has announced a ...
TMCnet

Sana Biotechnology Announces Positive Six-Month Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression

Sana is Incorporating the Tested Immune Evasion Technology to Develop SC451, a HIP-modified, Stem Cell-Derived Therapy as a One-Time Treatment for Patients with Type 1 Diabetes, with a Goal of Normal ...
FOX31 Denver

UniXell Biotechnology announces the first patient dosed with UX-DA001, an investigational autologous iPSC based cell therapy for the treatment of Parkinson's disease, in its ...

SHANGHAI, May 23, 2025 /PRNewswire/ -- Shanghai UniXell Biotechnology Co., Ltd. (UniXell Biotech), a biotech company dedicated to innovative cell therapies, announced the successful first ...